NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

Wow, the plot thickens.

Researchers in China found the experimental antiviral drug, dubbed remdesivir, didn't improve patients' conditions or reduce the amount of virus in their bloodstream, according to Financial Times. The publication cited a draft report the World Health Organization reportedly published by accident.

The coronavirus treatment hopeful also showed significant side effects in some patients and 18 were reportedly taken off of it.

The WHO has since removed the posting. Investigators didn't have permission to publish the study's results, Gilead Chief Medical Officer Merdad Parsey said in a written statement.

"We believe the post included inappropriate characterizations of the study," he said. "The study was terminated early due to low enrollment and, as a result, it was underpowered to enable statistically meaningful conclusions. As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease."

https://www.investors.com/news/technology/gild-stock-dives-coronavirus-treatment-reportedly-fails-key-test/?src=A00220&yptr=yahoo

Why was it terminated early due to low enrollment?
Why was there low enrollment? Surely not a shortage of available patients...

It may have been terminated early due to Gilead simply withdrawing the Remdesivir. Why would that be? Perhaps they're not keen on the Chinese randomised trial reaching an outcome.

And the vaccine developers really don't need an effective treatment getting in the way.

Fancy the WHO publishing interim data like this about an unapproved drug. Tut tut.

I think we need to hear a comment from Dr Buzdar about this.